

12. REFERENCIAS

1. European Society of Cardiology: *Guidelines for the diagnosis and treatment of pulmonary hypertension*. Eur Heart J 2009; 30: 2493-2537
2. Farber, H; Loscalzo, J. *Pulmonary Arterial Hypertension*. N Engl J Med. 2004; 351:1655-1665
3. Simmoneau G, Gatzoulis M, Adantia I, et al. *Updated clinical classification of pulmonary hypertension*. J Am Coll Cardiol. 2013; 62(25_S).
4. Humbert M et al. *Pulmonary arterial hypertension in France: results from a national registry*. Am J Respir Crit Care Med. 2006; 173:1023-1030.
5. McGoon M. Et al. *Pulmonary arterial hypertension: epidemiology and registries*. J Am Coll Cardiol. 2013; 62(25_S)
6. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. *Updated Treatment Algorithm of Pulmonary Arterial Hypertension*. J Am Coll Cardiol 2013; 62: D60–7.
7. Christman, B et al. *An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension*. New Engl J Med. 1992; 327: 70-5.
8. Giaid A, Saleh D. *Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension*. N Engl J Med. 1995 Jul; 333:214-221.
9. Giaid A. et al. *Expression of endothelin-1 in the lungs of patients with pulmonary hypertension*. N Engl J Med. 1993 Jun; 328:1732-1739.
10. Giaid A. *Nitric oxide and endothelin-1 in pulmonary hypertension*. CHEST. 1998; 114:208S-212S.
11. Ghofrani H et al. *Treatment of pulmonary arterial hypertension (PAH): Updated recommendations of the Cologne Consensus Conference 2011*. Int J Cardiol. 154S 2011; S20–S33
12. Galiè et al. *Guidelines for the diagnosis and treatment of pulmonary hypertension The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)*. Eur Heart J 2009; 30: 2493-2537
13. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G. *Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension*. Circulation 2005; 111:3105–3111
14. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Sitbon O, Speich R, Hoeper M, Behr J, Winkler J, Seeger W, for the AIR Study Group. *Inhaled iloprost in severe pulmonary hypertension*. N Engl J Med 2002; 347 :322–329.
15. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. *Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial*. Am J Respir Crit Care Med 2002; 165 :800–804.
16. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ. *Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil*. Eur Respir J 2006; 28 :1195–1203.
17. Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachieri JL. *Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension*. Chest 2006; 129 :1636–1643.
18. Skoro-Sajer N, Marthe-Lang I. *Selexipag for the treatment of pulmonary arterial hypertension*. Expert Opin Pharmacother 2014 Feb; 15(3):429-36.
19. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. *Long-term treatment with oral sildenafil is safe and improves functional capacity and*

- hemodynamics in patients with pulmonary arterial hypertension. Circulation* 2003; 108 :2066–2069.
20. Galie N, Brundage B, Ghofrani A, Oudiz R, Simonneau G, Safdar Z, Shapiro RS, White J, Chan M, Beardsworth A, Frumkin LR, Barst R. *Tadalafil therapy for pulmonary arterial hypertension. Circulation* 2009; 119 :2894–2903.
 21. Ghofrani H, Galie N, Grimminger F, Grünig E, Humbert M, Jing Z, Keogh A, Langleben D, Kilama M, Fritsch A, Neuser D, Rubin L. *Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med* 2013;369:330-40.
 22. Ghofrani H, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C. *Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med.* 2013 Jul 25;369(4):319-29.
 23. American Thoracic Society. *ATS Statement: Guidelines for the Six-Minute Walk Test.* ATS Official Documents. Marzo 2002.
 24. Tampion V et al. Oral Treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 study). *CHEST.* 2013 Sept 144(3):952-958.
 25. Zhi-Cheng J et al. Efficacy and Safety of Oral Treprostinil Monotherapy for the treatment of pulmonary arterial hypertension. *Circulation.* 2013; 127:624-633.
 26. Pulido T et al. Macitentan in morbidity and mortality in pulmonary arterial hypertension. *N Eng J Med.* Aug 2013; 369:809-818
 27. Barst RJ et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. *J Am Coll Cardiol.* 2006 May 16;47(10):2049-56.